Mayne Pharma Group Ltd. ( (MAYNF) ) has released its Q4 earnings. Here is a breakdown of the information Mayne Pharma Group Ltd. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mayne Pharma Group Ltd is an ASX-listed specialty pharmaceutical company focused on commercializing branded women’s health and dermatology pharmaceuticals, with a strong track record in developing oral drug delivery systems. The company’s latest financial report for the year ending June 30, 2025, highlights a 5.1% increase in revenue from continuing operations, reaching $408.1 million, and a 13% rise in gross profit to $247.3 million. Despite these gains, the company reported a net loss after tax of $90.1 million, an improvement from the previous year’s loss of $168.6 million. Key financial metrics include an adjusted EBITDA of $47 million, up from $22.9 million in the previous year, and a reported EBITDA of $18.4 million, a significant turnaround from a loss of $92.5 million in 2024. The company also announced strategic moves, including the acquisition of US rights to TWYNEO® and EPSOLAY®, and is navigating a proposed acquisition by Cosette Pharmaceuticals, which is currently under court review. Looking forward, Mayne Pharma aims to drive growth in its Women’s Health and Dermatology segments, leveraging recent investments and strategic partnerships to enhance its market position.